Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Journal of Medicinal Chemistry|November 30, 2020
Discovery of Potent, Highly Selective, and <i>In Vivo</i> Efficacious, Allosteric MALT1 Inhibitors by Iterative Scaffold MorphingCarole Pissot Soldermann, Oliver Simic, Martin Renatus, et al.
Molecular Cancer Therapeutics|August 15, 2019
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular CancerAndreas Weiss, Flavia Adler, Alexandra Buhles, et al.
Journal of Medicinal Chemistry|July 10, 2025
Promise and Challenge of β-Lactone Electrophiles to Target Aspartate 12 of Mutant KRAS<sup>G12D</sup>Balázs Budai, Andrea Vaupel, Callum J Dickson, et al.
Journal of Medicinal Chemistry|November 18, 2022
JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS<sup>G12C</sup> for the Treatment of Solid TumorsEdwige Lorthiois, Marc Gerspacher, Kim S Beyer, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2018
Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibitionFlorian A Siebzehnrübl, Kerstin A Raber, Yvonne K Urbach, et al.
Journal of Medicinal Chemistry|September 15, 2020
Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4Robin A Fairhurst, Thomas Knoepfel, Nicole Buschmann, et al.
JAMA|May 21, 2026
Screening Children for Early-Stage Type 1 DiabetesChristiane Winkler, Nadine Friedl, Renate Abt, et al.
Cancer Research|February 8, 2022
Transient Inhibition of the JAK/STAT Pathway Prevents B-ALL Development in Genetically Predisposed MiceAna Casado-García, Marta Isidro-Hernández, Ninad Oak, et al.
Cancer Discovery|April 11, 2022
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12CAndreas Weiss, Edwige Lorthiois, Louise Barys, et al.
Journal of Medicinal Chemistry|March 30, 2022
Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced MalignanciesYing Huang, Martin Sendzik, Jeff Zhang, et al.
Pageof 11